Targanta Therapeutics Overview

  • Founded
  • 1997
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 27
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $42M
Latest Deal Amount
  • Investors
  • 1

Targanta Therapeutics General Information

Description

Developer of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The company develops antibiotics for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Primary Office
  • 222 Third Street
  • Suite 2300
  • Cambridge, MA 02142
  • United States
+1 (514) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Targanta Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 26-Feb-2009 $42M 00000 0000 Completed Clinical Trials - Phase 3
6. IPO 10-Oct-2007 000.00 00000 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C3) 12-Feb-2007 000.00 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C2) 06-Jan-2005 0000 0000 000.00 Completed Generating Revenue
3. Later Stage VC (Series C1) 12-Mar-2002 000.00 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Dec-1999 $28.7M $30.3M 000.00 Completed Product Development
1. Seed Round 01-Dec-1997 $1.58M $1.58M 00.000 Completed Startup
To view Targanta Therapeutics’s complete valuation and funding history, request access »

Targanta Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C3 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C2 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C1 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 245,000 $0.000100 8% $199.5 $199.5 1x $199.5 1.35%
Series A 20,000 $0.000100 $101.12 $101.12 1x $101.12 0.15%
To view Targanta Therapeutics’s complete cap table history, request access »

Targanta Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
Mark Leuchtenberger President & Chief Executive Officer
Thomas Parr Ph.D Chief Scientific Officer
Daniel Char Vice President & General Counsel
Roger Miller Vice President, Operations & Manufacturing
You’re viewing 4 of 7 executive team members. Get the full list »

Targanta Therapeutics Board Members (1)

Name Representing Role Since
Randy Berholtz JD Self Board Member 000 0000
To view Targanta Therapeutics’s complete board members history, request access »

Targanta Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Targanta Therapeutics Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brookside Capital Venture Capital Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
GrowthWorks Venture Capital Minority 000 0000 000000 0
InterMune Corporation 000 0000 000000 0
Le Centre CDP Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »